We deliver insights across the biopharma value chain
Target & Biomarker Discovery
Uncover new biology with multimodal data and AI
Aignostics approach
We use archival tissue to generate custom, multimodal research cohorts on demand. These cohorts are methodically explored with advanced techniques like “explainable AI” to holistically identify novel targets and biomarkers based on multiple levels of biology, including:
- Clinical metadata
- H&E / IHC
- mIF
- Spatial Transcriptomics
- Proteomics
- scRNA-seq
- Methylomics
Aignostics signs multiyear target & biomarker discovery collaboration with Bayer
Bayer and Aignostics are co-developing a scalable platform for target and biomarker discovery.
AI-Driven Target Discovery in LUSC
The Aignostics-Bayer Target ID Platform integrates multi-omics data with explainable AI to identify complex biological patterns and reveal novel therapeutic hypotheses for cancers that lack effective treatments.
This LUSC case study validates the Platform's ability to stratify patients into distinct subgroups, recapitulate known cancer biology, and identify unique molecular signatures that could lead to the generation of novel therapeutic hypotheses.
Translational Research
Generate quantitative and predictive AI models
Aignostics approach
We have years of experience supporting complex translational research questions across a range of data modalities, including:
- Comprehensive tissue profiling and spatial analyses for H&E, mIF, and spatial transcriptomics images (e.g., cell classification, niche characterization, etc.)
- Precise quantification for challenging biomarkers in IHC images (e.g., staining intensity and localization)
- Prediction of biomarker expression and molecular mutations from H&E images
Featured Publications
Digital Diagnostics
Refine AI models for real world use in trials and clinics
Aignostics approach
We work with partners to validate and launch digital diagnostic tools that are developed in the context of translational research, including:
- Prescreening tools to determine if patients would benefit from additional diagnostic testing
- Scoring tools to accurately quantify complex biomarkers
- Positioning tools to determine what therapy a patient is most likely to benefit from